JP2021534202A5 - - Google Patents

Info

Publication number
JP2021534202A5
JP2021534202A5 JP2021509910A JP2021509910A JP2021534202A5 JP 2021534202 A5 JP2021534202 A5 JP 2021534202A5 JP 2021509910 A JP2021509910 A JP 2021509910A JP 2021509910 A JP2021509910 A JP 2021509910A JP 2021534202 A5 JP2021534202 A5 JP 2021534202A5
Authority
JP
Japan
Prior art keywords
formula
compound according
alkyl
note
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021509910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047309 external-priority patent/WO2020041344A1/en
Publication of JP2021534202A publication Critical patent/JP2021534202A/ja
Publication of JP2021534202A5 publication Critical patent/JP2021534202A5/ja
Pending legal-status Critical Current

Links

JP2021509910A 2018-08-20 2019-08-20 眼科疾患を処置する為の薬物の為の方法及び組成物 Pending JP2021534202A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719938P 2018-08-20 2018-08-20
US62/719,938 2018-08-20
PCT/US2019/047309 WO2020041344A1 (en) 2018-08-20 2019-08-20 Methods and compositions for drugs to treat ophthalmic diseases

Publications (2)

Publication Number Publication Date
JP2021534202A JP2021534202A (ja) 2021-12-09
JP2021534202A5 true JP2021534202A5 (cg-RX-API-DMAC7.html) 2022-08-26

Family

ID=69591159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509910A Pending JP2021534202A (ja) 2018-08-20 2019-08-20 眼科疾患を処置する為の薬物の為の方法及び組成物

Country Status (14)

Country Link
US (2) US12221447B2 (cg-RX-API-DMAC7.html)
EP (1) EP3840745A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021534202A (cg-RX-API-DMAC7.html)
KR (1) KR20210049857A (cg-RX-API-DMAC7.html)
CN (1) CN112654353A (cg-RX-API-DMAC7.html)
AU (1) AU2019326448A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109809A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003607A2 (cg-RX-API-DMAC7.html)
IL (1) IL280952A (cg-RX-API-DMAC7.html)
MX (1) MX2021002028A (cg-RX-API-DMAC7.html)
SG (1) SG11202101522WA (cg-RX-API-DMAC7.html)
TW (1) TW202021968A (cg-RX-API-DMAC7.html)
WO (1) WO2020041344A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003189A2 (pt) 2018-08-20 2021-05-11 Duke University métodos e composições de fármacos para tratar doenças oftálmicas
WO2024257328A1 (ja) * 2023-06-16 2024-12-19 千寿製薬株式会社 眼疾患モデル動物
JP7776899B1 (ja) 2024-06-14 2025-11-27 株式会社坪田ラボ 局所投与用の重症眼表面疾患の処置剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4153693B2 (ja) * 2001-04-25 2008-09-24 大日本住友製薬株式会社 新規なCaMKK阻害剤
GB0600764D0 (en) * 2006-01-13 2006-02-22 Crysoptix Ltd Organic compound, optical crystal film and method of production thereof
GB0600763D0 (en) * 2006-01-13 2006-02-22 Crysoptix Ltd 6, 7-dihydrobenzimidazo[1,2-C]quininazolin-6-one carboxylic acid, its esters and method of synthesis thereof
US8207185B2 (en) 2006-10-12 2012-06-26 Duke University CaMKKβ as a target for treating obesity
JP5464395B2 (ja) 2008-02-01 2014-04-09 大陽日酸株式会社 重水素化された芳香環又は複素環を有する化合物の製造方法
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
EP2334621A1 (en) 2008-09-16 2011-06-22 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
US20130253035A1 (en) 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
EP2638126B1 (en) * 2010-11-09 2015-02-18 Crysoptix K.K. Negative dispersion retardation plate and achromatic circular polarizer
SG194625A1 (en) 2011-05-23 2013-12-30 Sanofi Sa Process for the preparation of deuterated compounds containing n-alkyl groups
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態
AU2013361320A1 (en) 2012-12-20 2015-07-02 Concert Pharmaceuticals, Inc. Deuterated ALK inhibitors
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
BR112021003189A2 (pt) 2018-08-20 2021-05-11 Duke University métodos e composições de fármacos para tratar doenças oftálmicas

Similar Documents

Publication Publication Date Title
EA202193007A1 (ru) Соединения пирролидина
JP2013540776A5 (cg-RX-API-DMAC7.html)
JP2010510237A5 (cg-RX-API-DMAC7.html)
RU2013119869A (ru) Аналоги циклоспорина
JP2018518537A5 (cg-RX-API-DMAC7.html)
JP2016518437A5 (cg-RX-API-DMAC7.html)
JP2017537940A5 (cg-RX-API-DMAC7.html)
RU2011103741A (ru) Композиции и способы лечения заболевания сетчатки
IL286427B2 (en) Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
JP2010501584A5 (cg-RX-API-DMAC7.html)
JP2021516271A5 (cg-RX-API-DMAC7.html)
JP2018522866A5 (cg-RX-API-DMAC7.html)
JP2016522254A5 (cg-RX-API-DMAC7.html)
JP2017533922A5 (cg-RX-API-DMAC7.html)
JP2017524733A5 (cg-RX-API-DMAC7.html)
JP2021535112A5 (cg-RX-API-DMAC7.html)
WO2018075959A4 (en) Methods using hdac11 inhibitors
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2019535723A5 (cg-RX-API-DMAC7.html)
JP2017531689A5 (cg-RX-API-DMAC7.html)
JP2017531673A5 (cg-RX-API-DMAC7.html)
JP2015535247A5 (cg-RX-API-DMAC7.html)
JP2007504235A5 (cg-RX-API-DMAC7.html)
JP2013544786A5 (cg-RX-API-DMAC7.html)
JP2016525104A5 (cg-RX-API-DMAC7.html)